Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

DNQX disodium salt

  Cat. No.:  DC10673   Featured
Chemical Structure
1312992-24-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
DNQX is a elective non-NMDA antagonist
Cas No.: 1312992-24-7
Chemical Name: DNQX disodium salt
SMILES: O=C1[N-]C2=C(C=C([N+]([O-])=O)C([N+]([O-])=O)=C2)[N-]C1=O.[Na+].[Na+]
Formula: C8H2N4Na2O6
M.Wt: 296.100
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: DNQX (FG 9041) disodium salt, a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively)[1].
In Vivo: DNQX (FG 9041), a specific AMPA receptor antagonist, given as either a 5 mg/kg or 10 mg/kg intraperitoneal dose or into the lateral cerebral ventricle (5 μl of 0.5 mg/ml) significantly diminishes phencyclidine (PCP) (40 mg/kg) and ketamine (80, 100, 120 mg/kg) hsp70 induction in the posterior cingulate and retrosplenial cortex[3].
In Vitro: DNQX (FG 9041) disodium salt selectively depolarizes thalamic reticular nucleus (TRN) neurons[2].
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC8824 Traxoprodil Traxoprodil is an NMDA ε 2 (NR2B) antagonist that has been studied as an alternative to serotonin selective reuptake inhibitors.
DC7863 Talampanel (GYKI 53773) Talampanel is a novel anticonvulsant that acts as an allosteric inhibitor of the AMPA receptor.
DC8175 Rapastinel(GLYX-13) Rapastinel(GLYX-13) is a NMDA receptor partial agonist that acts at the glycine site.
DC8307 QNZ46 QNZ is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively).
DC7226 Perampanel(E2007) Perampanel(E2007; ER 155055-90) is a selective noncompetitive AMPA-type glutamate receptor antagonist which has demonstrated anticonvulsant activity in experimental seizure models and antiepileptic activity in clinical trials.
DC7989 PEPA PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity.
DC11382 NYX-2925 NYX-2925 is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.
DC7576 NVP-AAM077 NVP-AAM077 is a potent antagonist for NMDA receptors.
DC11406 NBQX NBQX is a potent aminomethylphosphonic acid receptor (AMPAR) antagonist with an IC50 of 0.7 ± 0.1 μM.
DC7194 MDL 29951 MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.
X